Business Wire

THALES

6.6.2022 14:02:12 CEST | Business Wire | Press release

Share
Thales and Palo Alto Networks Deliver New Security Integrations to Help Organisations Implement Zero Trust Security

As organisations continue their digital transformation journeys and move more of their workloads, networking, and security frameworks to the cloud, there is increasing pressure for businesses to rollout sufficiently robust security solutions to safeguard their networks. A long-standing collaboration between the two global cybersecurity leaders, Thales and Palo Alto Networks, will help support this widespread cloud migration, allowing organisations to implement Zero Trust security systems at scale. Through three technology integrations, businesses will gain access to Internal Resources within a robust, highly resilient security architecture.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220606005079/en/

This news comes at a time where cloud transformation at enterprise-level is occurring at pace to support an increasingly hybrid working world. In line with this shift, it is critical that businesses secure distributed IT environments that no longer have a defined physical security perimeter. The combination of identity aware contextual access controls and multi-factor authentication systems will enable secure cloud transformation whilst supporting remote workforces, allowing employees to safely access any resource, from anywhere, and on any device.

Three key integrations

The integrations will minimise the threat of data breaches from identity compromise by implementing strong, adaptive authentication at the network edge and by ensuring automated remediation workflows in the event of an untrusted access event.

By integrating Thales’ SafeNet Trusted Access across Palo Alto Networks Prisma® Access, GlobalProtect, ML-Powered Next Generation Firewalls, and Cortex® XSOAR technologies, businesses will be able to deploy a Zero Trust model across a suite of solutions. Organisations will benefit from secure and adaptive multi-factor authentication, access management across edge solutions, network security policies, incident response and threat intelligence management.

“Thales has partnered with us to help support customers through their digital transformation journeys, and in collaboration we are well primed to provide a zero trust approach with authentication, SOC security and ZTNA solutions. With these integrations, businesses are able to seamlessly secure access to hybrid and cloud environments, detect suspicious account activity, automatically trigger alerts and enforce stronger access policies in real-time,” said Tana Rosenblatt, VP Technology Partnerships, at Palo Alto Networks.

“The business threat landscape is evolving rapidly, leading to an increase in the scale and complexity of risks being faced by many of our clients. As organisations move their network security to the cloud, it becomes more difficult to implement holistic security controls. We are excited to be able to work with Palo Alto Networks and offer organisations a clear path towards identity-aware Zero Trust security.

By applying and enforcing adaptive and multi-factor authentication at the network edge, and by responding to and stopping untrusted access events in real-time, Thales and Palo Alto Networks ensure organisations can make the move to the cloud successfully and securely,” concluded Francois Lasnier, VP Access Management Products at Thales.

For businesses looking to roll out Zero Trust frameworks within their networks, Thales and Palo Alto Networks security solutions are available to integrate now. To learn more about rolling out Zero Trust frameworks using Thales and Palo Alto Networks security solutions, join our RSA Conference roundtable session that discusses identity centric Zero Trust with Palo Alto Networks by reserving one of the limited seats here .

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum technologies – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organizations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.

Thales has 81,000 employees in 68 countries. In 2021, the Group generated sales of €16.2 billion.

PLEASE VISIT

Thales Group
Security

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye